Publications by authors named "ME Hanson"

Claim this Profile
A
A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
J Wassil, M Sisti, J Fairman, B Rankin, J Clark, M E Hanson

Vaccine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Jakub K Simon, Stephen B Kennedy, Barbara E Mahon, Sheri A Dubey, Rebecca J Grant-Klein, Mary E Hanson

Vaccine· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuation and recovery of an avoidance response to a chemical antipredator cue in an invasive fish: implications for use as a repellent in conservation.
C Michael Wagner, Jason D Bals, Mikaela E Hanson, Anne M Scott

Conserv Physiol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Rebecca F Grais, Stephen B Kennedy, Barbara E Mahon, Sheri A Dubey, Rebecca J Grant-Klein, Mary E Hanson

Lancet Microbe· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Pandemic Vaccines: ERVEBO Case Study.
Jayanthi Wolf, Risat Jannat, Sheri Dubey, Sean Troth, Matthew T Onorato, Mary E Hanson

Vaccines (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to: Renal Impairment, Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.
Yoav Golan, Herbert L DuPont, Fernando Aldomiro, Erin H Jensen, Mary E Hanson

Open Forum Infect Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Emilio Bouza, Oliver A Cornely, Antonio Ramos-Martinez, Robert Plesniak, Misoo C Ellison, Mary E Hanson

Eur J Clin Microbiol Infect Dis· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thermal injury initiates pervasive fibrogenesis in skeletal muscle.
Camille R Brightwell, Madeline E Hanson, Amina El Ayadi, Anesh Prasai, Ye Wang

Am J Physiol Cell Physiol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging features of disseminated xanthogranulomatous inflammation in eclectus parrots (Eclectus roratus).
Melissa E Hanson, Taryn A Donovan, Katherine Quesenberry, Amanda Dewey, Cindy Brown

Vet Radiol Ultrasound· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Impairment, Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.
Yoav Golan, Herbert L DuPont, Fernando Aldomiro, Erin H Jensen, Mary E Hanson

Open Forum Infect Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.
Anirban Basu, Vimalanand S Prabhu, Mary Beth Dorr, Yoav Golan, Erik R Dubberke, Mary E Hanson

Open Forum Infect Dis· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Dale N Gerding, Ciaran P Kelly, Galia Rahav, Christine Lee, Erik R Dubberke, Mary E Hanson

Clin Infect Dis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.
Vimalanand S Prabhu, Oliver A Cornely, Yoav Golan, Erik R Dubberke, Sebastian M Heimann, Mary E Hanson

Clin Infect Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.
Jérémie Abtan, Deepak L Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Mary E Hanson

Clin Cardiol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Jianming Ba, Ping Han, Guoyue Yuan, Zhaohui Mo, Changyu Pan, Mary E Hanson

J Diabetes· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database.
Mehul D Patel, David Wu, Monica Reed Chase, Panagiotis Mavros, Kim Heithoff, Mary E Hanson

J Manag Care Spec Pharm· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
Peter P Toth, Alberico L Catapano, Michel Farnier, Joanne Foody, Joanne E Tomassini, Mary E Hanson

Am J Cardiol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.
Jérémie Abtan, Deepak L Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Mary E Hanson

Clin Cardiol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Yoshiaki Ogawa, Michinori Ogura, Kensei Tobinai, Kiyoshi Ando, Tatsuya Suzuki, Mary E Hanson

Int J Hematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Olivier Descamps, Joanne E Tomassini, Jianxin Lin, Adam B Polis, Arvind Shah, Mary E Hanson

Atherosclerosis· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.
Itori Saito, Kyoichi Azuma, Taro Kakikawa, Nobuyuki Oshima, Mary E Hanson

Lipids Health Dis· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
Teddy Kosoglou, Bharath Kumar, Paul Statkevich, James E Schiller, Bhavna Kantesaria, Mary E Hanson

Clin Pharmacol Drug Dev· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials.
Hiromi Rakugi, Takuya Tsuchihashi, Kazuyuki Shimada, Hirotaka Numaguchi, Chisato Nishida, Mary E Hanson

Hypertens Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials.
Sreevalsa Unniachan, David Wu, Srinivasan Rajagopalan, Mary E Hanson, Kenji P Fujita

J Clin Hypertens (Greenwich)· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
Teddy Kosoglou, James Hubbell, Bhavna Kantesaria, Mary E Hanson, David L Cutler

Clin Pharmacol Drug Dev· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis